Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single Ascending Dose Study, to Assess the Safety and Pharmacokinetics of Intravenous ATX101 in Healthy Participants

NCT07107802 is registered in ClinicalTrials.gov with Aurobac Therapeutics SAS as lead sponsor.

NCT NCT07107802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07107802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single Ascending Dose Study, to Assess the Safety and Pharmacokinetics of Intravenous ATX101 in Healthy Participants
Lead sponsor
Aurobac Therapeutics SAS
Phase
Phase 1
Overall status
Completed
Start date
July 19, 2025
Completion date
October 24, 2025
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants